Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels.

Melander, Arne LU ; Folino-Gallo, P ; Walley, T ; Schwabe, U ; Groop, P-H ; Klaukka, T ; Vallano, A ; Laporte, J-R ; Gallego, M and Schiappa, M , et al. (2006) In Diabetologia 49(9). p.2024-2029
Abstract
Aims/hypothesis The aim of this study was to compare developments in the utilisation of antihyperglycaemic drugs (AHGDs) in ten European countries. Subhect and methods Data on the yearly utilisation of insulin and oral AHGDs were collected from public registers in Denmark, Finland, Norway, Sweden, Belgium, England, Germany, Italy, Portugal and Spain, and were expressed as defined daily doses per 1,000 inhabitants per day. Results Total AGHD utilisation increased everywhere, but at different rates and levels. Insulin utilisation doubled in England and Germany, but hardly changed in Belgium, Portugal or Italy. Sulfonylurea utilisation doubled in Spain, England and Denmark but was reduced in Germany and Sweden. Metformin utilisation increased... (More)
Aims/hypothesis The aim of this study was to compare developments in the utilisation of antihyperglycaemic drugs (AHGDs) in ten European countries. Subhect and methods Data on the yearly utilisation of insulin and oral AHGDs were collected from public registers in Denmark, Finland, Norway, Sweden, Belgium, England, Germany, Italy, Portugal and Spain, and were expressed as defined daily doses per 1,000 inhabitants per day. Results Total AGHD utilisation increased everywhere, but at different rates and levels. Insulin utilisation doubled in England and Germany, but hardly changed in Belgium, Portugal or Italy. Sulfonylurea utilisation doubled in Spain, England and Denmark but was reduced in Germany and Sweden. Metformin utilisation increased greatly everywhere. There were two- to three-fold differences in AHGD utilisation even between neighbouring countries. In Finland, there were more users of both insulin (+120%) and oral AHGDs (+80%) than in Denmark, and the daily oral AHGD doses were higher. In Denmark and Sweden, AHGD utilisation was equal in subjects aged < 45 years, but in those >= 45 years of age, both insulin and oral AHGD utilisation were twice as high in Sweden. Conclusions/interpretation The ubiquitous increase in AHGD utilisation, particularly metformin, seems logical, considering the increasing prevalence of type 2 diabetes and the results of the UK Prospective Diabetes Study. However, the large differences even between neighbouring countries are more difficult to explain, and suggest different habits and attitudes in terms of screening and management of type 2 diabetes. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
insulin, international comparison, metformin (biguanides), international, diabetes mellitus, treatment of diabetes, antihyperglycaemic drug utilisation, sulfonylurea, variation in drug utilisation, antidiabetic drug utilisation
in
Diabetologia
volume
49
issue
9
pages
2024 - 2029
publisher
Springer
external identifiers
  • wos:000239548800007
  • scopus:33746778857
ISSN
1432-0428
DOI
10.1007/s00125-006-0331-3
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Family Medicine (013241010), Community Medicine (013241810), Reconstructive Surgery (013240300)
id
87558f65-9a96-4683-a1f5-4770b2131d93 (old id 158810)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16865360&dopt=Abstract
date added to LUP
2016-04-01 12:23:35
date last changed
2021-03-24 03:35:57
@article{87558f65-9a96-4683-a1f5-4770b2131d93,
  abstract     = {Aims/hypothesis The aim of this study was to compare developments in the utilisation of antihyperglycaemic drugs (AHGDs) in ten European countries. Subhect and methods Data on the yearly utilisation of insulin and oral AHGDs were collected from public registers in Denmark, Finland, Norway, Sweden, Belgium, England, Germany, Italy, Portugal and Spain, and were expressed as defined daily doses per 1,000 inhabitants per day. Results Total AGHD utilisation increased everywhere, but at different rates and levels. Insulin utilisation doubled in England and Germany, but hardly changed in Belgium, Portugal or Italy. Sulfonylurea utilisation doubled in Spain, England and Denmark but was reduced in Germany and Sweden. Metformin utilisation increased greatly everywhere. There were two- to three-fold differences in AHGD utilisation even between neighbouring countries. In Finland, there were more users of both insulin (+120%) and oral AHGDs (+80%) than in Denmark, and the daily oral AHGD doses were higher. In Denmark and Sweden, AHGD utilisation was equal in subjects aged &lt; 45 years, but in those &gt;= 45 years of age, both insulin and oral AHGD utilisation were twice as high in Sweden. Conclusions/interpretation The ubiquitous increase in AHGD utilisation, particularly metformin, seems logical, considering the increasing prevalence of type 2 diabetes and the results of the UK Prospective Diabetes Study. However, the large differences even between neighbouring countries are more difficult to explain, and suggest different habits and attitudes in terms of screening and management of type 2 diabetes.},
  author       = {Melander, Arne and Folino-Gallo, P and Walley, T and Schwabe, U and Groop, P-H and Klaukka, T and Vallano, A and Laporte, J-R and Gallego, M and Schiappa, M and Røder, M and Kampmann, J and de Swaef, A and Åberg, Magnus and Månsson, Nils-Ove and Lindblad, Ulf},
  issn         = {1432-0428},
  language     = {eng},
  number       = {9},
  pages        = {2024--2029},
  publisher    = {Springer},
  series       = {Diabetologia},
  title        = {Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels.},
  url          = {http://dx.doi.org/10.1007/s00125-006-0331-3},
  doi          = {10.1007/s00125-006-0331-3},
  volume       = {49},
  year         = {2006},
}